Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children

Bone Marrow Transplantation

Volumn 26, Issue 4, 2000, Pages 405-411

  Peters, C ^a   Minkov, M ^a   Gadner, H ^a   Klingebiel, T ^b   Vossen, J ^c   Locatelli, F ^d   Cornish, J ^e   Ortega, J ^f   Bekasi, A ^g   Souillet, G ^h   Stary, J ⁱ   Niethammer, D ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PAVIA   (Italy)

^e BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^f Vall d'Hebron   (Spain)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h HÔPITAL DEBROUSSE   (France)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Allogeneic bone marrow transplantation; Children; Graft versus host disease; Prophylaxis; Therapy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; FOLINIC ACID; IMTIX; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY LYM 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OKT 3; PREDNISOLONE; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; POLICY; PRIORITY JOURNAL; PUVA; STANDARDIZATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT PLANNING;

EID: 0033845471     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702524     Document Type: Article

References (69)

1. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation
2. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
3. Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors
4. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants
5. Survey of GVHD prophylaxis for pediatric stem cell transplantation in Europe: A report from the EBMT paediatric diseases working party
6. The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD?
7. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients
8. Inflammatory reactions induced by pretransplant conditioning - An alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?
9. Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose
10. An influence diagram for assessing GVHD prophylaxis after bone marrow transplantation in children
11. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT)
12. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment
13. Graft-versus-host disease
14. Obstructive lung disease in children after allogeneic bone marrow transplantation
15. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease
16. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
17. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation
18. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children
19. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children
20. Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: A report from the EBMT working party on paediatric diseases
21. Survey of supportive care standards for paediatric allogeneic stem cell transplantation patients in Europe: A first report from the EBMT paediatric diseases working party
22. 1994 consensus conference on acute GVHD grading
23. Conversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A
24. Practical aspects in the use of cyclosporin in paediatric nephrology
25. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: Evaluation of early monitoring of engraftment
26. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
27. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device
28. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome
29. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation
30. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation
31. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: A multicentric pilot study including 15 patients
32. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies
33. Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease
34. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
35. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies
36. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease
37. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease
38. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease
39. Pulse glucocorticoid therapy. The 'big shot' revisited
40. Thalidomide for the treatment of chronic graft-versus-host disease
41. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
42. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants
43. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
44. Photochemotherapy improves chronic cutaneous graft-versus-host disease
45. PUVA therapy for chronic cutaneous graft-vs-host disease
46. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease
47. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation
48. Graft-versus-host disease in children: The AIEOP-BMT group experience with cyclosporin A
49. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation
50. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
51. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study
52. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings
53. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation
54. Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect (letter)
55. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease
56. Graft-versus-host disease prophylaxis with low-dose cyclosprine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial
57. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation
58. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation
59. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation
60. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia
61. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival
62. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children
63. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease
64. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation
65. Cyclosporin A and chronic graft versus host disease
66. Management of acute graft-versus-host disease
67. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
68. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation
69. PUVA therapy for drug-resistant graft-versus-host disease